These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39048727)

  • 1. MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Epstein JB; Jensen SB; Gueiros LA; van Leeuwen SJM; Kandwal A; Vissink A; Elad S
    Support Care Cancer; 2024 Jul; 32(8):551. PubMed ID: 39048727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Jensen SB; Vissink A; Bonomo P; Santos-Silva AR; Gueiros LA; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):548. PubMed ID: 39048728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.
    Zadik Y; Raber-Durlacher JE; Epstein JB; Majorana A; Laheij A; Bardellini E; Blijlevens N; Elad S
    Support Care Cancer; 2024 Jul; 32(8):546. PubMed ID: 39048807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.
    Mercadante V; Jensen SB; Smith DK; Bohlke K; Bauman J; Brennan MT; Coppes RP; Jessen N; Malhotra NK; Murphy B; Rosenthal DI; Vissink A; Wu J; Saunders DP; Peterson DE
    J Clin Oncol; 2021 Sep; 39(25):2825-2843. PubMed ID: 34283635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.
    Villa A; Epstein JB; Yarom N; Hong C; Fulop C; Bossi P; Elad S
    Support Care Cancer; 2024 Jul; 32(8):549. PubMed ID: 39048808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASCC/ISOO clinical practice statement: Current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation.
    Raber-Durlacher JE; Zadik Y; Treister NS; Stempler N; Bruno JS; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):550. PubMed ID: 39048882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.
    Raber-Durlacher JE; Treister NS; Zadik Y; Dean DR; Miranda-Silva W; Fregnani ER; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):545. PubMed ID: 39048762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients.
    Jensen SB; Vissink A; Limesand KH; Reyland ME
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and management of dry mouth and its complications in rheumatology practice.
    Khavandgar Z; Warner BM; Baer AN
    Expert Rev Clin Immunol; 2024; 20(1):1-19. PubMed ID: 37823475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xerostomia/Salivary Gland Hypofunction: Diagnosis and Management.
    Zunt SL
    Compend Contin Educ Dent; 2018 Jun; 39(6):365-369; quiz 371. PubMed ID: 29847962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xerostomia and hypofunction of the salivary glands in cancer therapy.
    Jensen SB; Pedersen AM; Reibel J; Nauntofte B
    Support Care Cancer; 2003 Apr; 11(4):207-25. PubMed ID: 12673459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xerostomia: evaluation of a symptom with increasing significance.
    Fox PC; van der Ven PF; Sonies BC; Weiffenbach JM; Baum BJ
    J Am Dent Assoc; 1985 Apr; 110(4):519-25. PubMed ID: 3858368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women.
    Navazesh M; Mulligan R; Komaroff E; Redford M; Greenspan D; Phelan J
    J Dent Res; 2000 Jul; 79(7):1502-7. PubMed ID: 11005735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary gland dysfunction and xerostomia in Sjögren's syndrome.
    Jensen SB; Vissink A
    Oral Maxillofac Surg Clin North Am; 2014 Feb; 26(1):35-53. PubMed ID: 24287192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs.
    Plemons JM; Al-Hashimi I; Marek CL;
    J Am Dent Assoc; 2014 Aug; 145(8):867-73. PubMed ID: 25082939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Workshop on Oral Medicine VIII: Development of a core outcome set for dry mouth: a systematic review of outcome domains for salivary hypofunction.
    Simms ML; Kuten-Shorrer M; Wiriyakijja P; Niklander SE; Santos-Silva AR; Sankar V; Kerr AR; Jensen SB; Riordain RN; Delli K; Villa A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2023 Jun; 135(6):804-826. PubMed ID: 37183064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry mouth: Xerostomia and salivary gland hypofunction.
    Frydrych AM
    Aust Fam Physician; 2016 Jul; 45(7):488-92. PubMed ID: 27610431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAOM Clinical Practice Statement: Subject: Clinical management of cancer therapy-induced salivary gland hypofunction and xerostomia.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):310-2. PubMed ID: 27432150
    [No Abstract]   [Full Text] [Related]  

  • 20. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.
    Jensen SB; Pedersen AM; Vissink A; Andersen E; Brown CG; Davies AN; Dutilh J; Fulton JS; Jankovic L; Lopes NN; Mello AL; Muniz LV; Murdoch-Kinch CA; Nair RG; Napeñas JJ; Nogueira-Rodrigues A; Saunders D; Stirling B; von Bültzingslöwen I; Weikel DS; Elting LS; Spijkervet FK; Brennan MT;
    Support Care Cancer; 2010 Aug; 18(8):1039-60. PubMed ID: 20237805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.